Date: 2014-10-03
Type of information: Nomination
Compound: chief commercial officer
Company: Ophthotech (USA - NY)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 3, 2014, Ophthotech announced that Todd N. Smith has joined the Company as Senior Vice President and Chief Commercial Officer, a new position at the Company. Mr. Smith will be responsible for developing and implementing Ophtotech\'s commercial strategy and establishing a commercial infrastructure of high-quality marketing, product access and sales teams as the Company continues to advance its pipeline and begins to prepare for a potential first product launch with Fovista®. Mr. Smith will report directly to Ophthotech\'s Chief Executive Officer and Chairman of the Board, David R. Guyer, M.D. He will also serve as a member of Ophthotech\'s senior leadership team.
- Mr. Smith has more than 20 years of pharmaceutical and biotechnology sales and marketing experience and a record of achieving commercial excellence. He has either led or participated in more than 12 product launches including several billion dollar brands and product portfolios. He has built high-performing commercial and marketing teams at top companies including Bayer, Abbott, Horizon Pharma, Agouron and Fenwell Inc. Mr. Smith most recently served as Executive Vice President and Chief Commercial Officer at Horizon Pharma where he was instrumental in building and implementing the successful launch of that company\'s pain product portfolio. He also served as Vice President, Global Marketing, Strategy and Business Development at Fenwal, a global medical device company. In that capacity, he was responsible for Fenwal\'s global product portfolio and its strategic planning and business development initiatives. Mr. Smith also led both sales and marketing activities for the virology franchise at Abbott, including the launch of Kaletra® tablets (a critical life-cycle reformulation), where global sales grew to more than $1 billion.
Financial terms:
Latest news:
Is general: Yes
